ADIL earnings analysis
What we found in ADIL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The filing provides no reported revenue, margin, current-quarter EPS, or free-cash-flow figures in the supplied excerpt; it instead reflects a clinical-stage biotechnology company with no product revenue and a $52.0 million Q2 2026 net loss. Liquidity is a major concern: the company used $8.0 million in operating cash during the quarter, states that cash will not fund the next 12 months, and expects to need additional financing despite $27.6 million of 2026 equity proceeds. The newly identified material weakness, Nasdaq equity deficiency below $2.5 million, and substantial potential dilution further weaken the outlook, although management provided AT177 milestones into the first half of 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $27.6M of 2026 equity proceeds
- The company received approximately $27.6 million of net proceeds from equity issuances during 2026, providing near-term funding for operations and development of AT177 and AD04.
- AT177 development milestones outlined
- Management expects to file an IND for AT177 and initiate a Phase 1a SAD/MAD study in the first half of 2027, with a proof-of-concept readout in ulcerative colitis patients expected in the first half of 2028.
- AhR patent protection through 2042
- The company reports composition-of-matter patent protection for its AhR program through 2042, supporting a potentially long intellectual-property runway if the program succeeds.
- Focused post-Merger pipeline
- The filing states that substantially all, or greater than 90%, of the fair value acquired in the Merger is concentrated in Azora’s colon-targeted AhR program, creating a focused development strategy around AT177.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern and financing risk
- The company incurred a $52.0 million net loss and used $8.0 million of cash in operations during the three months ended June 30, 2026. Management states that existing cash is not expected to fund operations for the next 12 months and is only anticipated to fund needs into the second half of 2027, requiring additional near-term fundraising.
- Nasdaq listing deficiency
- As of June 30, 2026, stockholders’ equity did not meet Nasdaq’s $2.5 million continued-listing requirement. The company expects a deficiency notice and must obtain conditional approval of its Nasdaq Listing Application before stockholder approval of the proposed change of control.
- Material weakness in controls
- Management identified a material weakness as of June 30, 2026 in internal control over financial reporting related to non-routine, complex transactions associated with the Merger, Financing and Azora Note Exchange. The CEO and CFO concluded that disclosure controls and procedures were not effective at quarter-end; remediation will involve third-party accounting consultants.
- Substantial potential dilution
- The Series A Preferred Stock is convertible into 12,930,617 common shares, while outstanding warrants and options cover 1,240,076 and 1,646,685 shares, respectively, creating substantial potential dilution if the related approvals and exercises occur.
What they said about what is next.
No numeric revenue or EPS guidance is provided in the filing. Management states that cash is anticipated to fund needs into the second half of 2027, commercialization is not expected to begin until 2028 or later, and an IND filing and Phase 1a study for AT177 are expected in the first half of 2027.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 8, 2026
- Adial Pharmaceuticals, Inc. reported a net loss of $2.0 million for Q1 2026, an improvement compared to the $2.228 million loss for Q1 2025. The company has no revenue streams yet and expects to continue burning cash as…
- 10-K · March 5, 2026
- Adial is a pre-revenue, clinical-stage biopharma focused on AD04 for alcohol use disorder. The 10-K highlights progress on regulatory planning (FDA EOP2 alignment) and a March 3, 2026 collaboration framework with…
- 10-Q · November 13, 2025
- Adial reported a Q3 2025 net loss of $1,793,651 (loss per share $0.08), an improvement from Q3 2024 net loss of $2,191,803 (loss per share $0.38). Operating expenses fell to $1,764,078 in Q3 2025 from $2,211,474 a year…
- 10-Q · August 13, 2024
- Adial reported a Q2 net loss of $2,458,298 (loss per share $0.59) and a six‑month loss from continuing operations of $8,934,858, driven largely by a $4,464,427 inducement expense and a $412,343 loss on its equity method…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ADIL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever